

JPET #140350

**Title Page**

**Centrally active allosteric potentiators of the M<sub>4</sub> muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotor activity in rats**

**Ashley E. Brady, Carrie K. Jones, Thomas M. Bridges, J. Phillip Kennedy, Analisa D. Thompson, Justin U. Heiman, Micah L. Breininger, Patrick R. Gentry, Huiyong Yin, Satyawan B. Jadhav, Jana K. Shirey, P. Jeffrey Conn, Craig W. Lindsley.**

Departments of Pharmacology (A.E.B., C.K.J., T.M.B., A.D.T., J.U.H., H.Y., S.B.J., J.K.S., P.J.C, and C.W.L.) and Chemistry (J.P.K., M.L.B., P.R.G., H.Y., C.W.L.), Vanderbilt Program in Drug Discovery (H.Y., P.J.C, and C.W.L.), Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA

JPET #140350

## Running Title Page

**Running Title:** Centrally active M<sub>4</sub> positive allosteric modulators

**Corresponding author:** Professor Craig W. Lindsley, Departments of Pharmacology and Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Nashville, TN 37232-6600, USA.

Email: [craig.lindsley@vanderbilt.edu](mailto:craig.lindsley@vanderbilt.edu); Ph: 615-322-8700; FAX: 615-343-6532

Number of Text Pages: 37

Number of Tables: 2

Number of Figures: 9

Number of References: 31

Number of words in Abstract: 229

Number of words in Introduction: 707

Number of words in Discussion: 1425

**Abbreviations:** VU0152099, 3-amino-*N*-(benzo[d][1,3]dioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-*b*]pyridine carboxamide; VU0152100, 3-amino-*N*-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-*b*]pyridine carboxamide; ACh, acetylcholine; AD, Alzheimer's Disease; CNS, central nervous system; CRC, concentration response curve; DCC, dicyclohexylcarbodiimide; DIEA, diisopropylethyl amine; GPCRs, G protein-coupled receptors; HOBt, hydroxybenzotriazole; *i.p.*, intraperitoneally; mAChR, muscarinic acetylcholine receptor; M<sub>4</sub>, muscarinic acetylcholine receptor subtype 4; NMDA, *N*-Methyl-D-aspartate; PAM, positive allosteric modulator; P-gp, P-glycoprotein; SAR, structure-activity-relationship.

**Recommended Section:** Neuropharmacology

JPET #140350

## Abstract

Previous clinical and animal studies suggest that selective activators of M<sub>1</sub> and/or M<sub>4</sub> muscarinic acetylcholine receptors (mAChRs) have potential as novel therapeutic agents for treatment of schizophrenia and Alzheimer's disease. However, highly selective centrally penetrant activators of either M<sub>1</sub> or M<sub>4</sub> have not been available, making it impossible to determine the *in vivo* effects of selective activation of these receptors. We previously identified VU10010 as a potent and selective allosteric potentiator of M<sub>4</sub> mAChRs. However, unfavorable physiochemical properties prevented use of this compound for *in vivo* studies. We now report that chemical optimization of VU10010 has afforded two centrally penetrant analogs, VU0152099 and VU0152100, that are potent and selective positive allosteric modulators of M<sub>4</sub>. VU0152099 and VU0152100 had no agonist activity, but potentiated responses of M<sub>4</sub> to acetylcholine. Both compounds were devoid of activity at other mAChR subtypes or at a panel of other GPCRs. The improved physiochemical properties of VU0152099 and VU0152100 allowed *in vivo* dosing and evaluation of behavioral effects in rats. Interestingly, these selective allosteric potentiators of M<sub>4</sub> reverse amphetamine-induced hyperlocomotion in rats, a model that is sensitive to known antipsychotic agents and to non-selective mAChR agonists. This is consistent with the hypothesis that M<sub>4</sub> plays an important role in regulating midbrain dopaminergic activity and raises the possibility that positive allosteric modulation of M<sub>4</sub> may mimic some of the antipsychotic-like effects of less selective mAChR agonists.

JPET #140350

## Introduction

To date, five muscarinic acetylcholine receptor (mAChR) subtypes have been identified ( $M_1$ - $M_5$ ) and play important roles in mediating the actions of ACh in the peripheral and central nervous systems (Wess, 1996). Of these,  $M_1$  and  $M_4$  are the most heavily expressed in the CNS and represent attractive therapeutic targets for cognition, Alzheimer's Disease (AD) and schizophrenia (Bymaster et al., 2002; Messer, 2002; Raedler et al., 2007). In contrast, the adverse effects of cholinergic agents are thought to be primarily due to activation of peripheral  $M_2$  and  $M_3$  mAChRs (Bymaster et al., 2003a,b). Due to the high sequence homology and conservation of the orthosteric ACh binding site among the mAChR subtypes, development of chemical agents that are selective for a single subtype has been largely unsuccessful, and in the absence of highly selective activators of  $M_4$ , it has been impossible to test the role of selective  $M_4$  activation. Clinical trials with xanomeline (**1**) (Fig. 1), an  $M_1/M_4$  preferring orthosteric agonist, demonstrated efficacy as both a cognition enhancing agent, and as an antipsychotic agent (Bodick et al., 1997; Shekhar et al., 2001, 2008). In follow-up studies in rats, xanomeline displayed an antipsychotic-like profile comparable to clozapine (Stanhope et al., 2001). However, a long standing question concerned whether or not the antipsychotic efficacy or antipsychotic-like activity in animal models is mediated by activation of  $M_1$ ,  $M_4$ , or a combination of both receptors. Data from mAChR knock-out mice led to the suggestion that a selective  $M_1$  agonist would be beneficial for cognition, whereas an  $M_4$  agonist would provide antipsychotic activity for the treatment of schizophrenia (Felder et al., 2001; Bymaster et al., 2003a,b). This proposal is further supported by recent studies demonstrating that  $M_4$  receptors modulate the dynamics of cholinergic and dopaminergic neurotransmission and that loss of  $M_4$  function results in a state of dopamine hyperfunction (Tzavara et al., 2004). These data, coupled with findings that schizophrenic patients have altered hippocampal  $M_4$ , but not  $M_1$ , receptor expression (Scarr et al., 2007), suggest that selective activators of  $M_4$  may provide a novel treatment strategy for schizophrenia patients. However, multiple studies suggest that  $M_1$  may also play an important role in the antipsychotic effects of mAChR agonists and the relative contributions of  $M_1$  and  $M_4$  to the antipsychotic efficacy of xanomeline or antipsychotic-like effects of this compound in animal models are not known.

JPET #140350

Unfortunately, the lack of highly selective, systemically active activators of M<sub>1</sub> and M<sub>4</sub> has made it difficult to fully evaluate the effects of activation of these mAChR subtypes in animal models.

Recently, we reported discovery of a number of positive allosteric modulators for class C GPCRs that bind to allosteric sites, provide high levels of subtype selectivity and display behavioral effects *in vivo* comparable to direct acting agonists (O'Brien et al., 2003, 2004; Lindsley et al., 2004; Kinney et al., 2005; Galici et al., 2006; Hemstapat et al., 2006; Marino and Conn, 2006; Zhao et al., 2007). In addition, we identified a highly selective positive allosteric modulator of M<sub>4</sub> termed VU10010 (**2**) (Fig. 1) (Shirey et al., 2008). This compound induces a 47-fold potentiation of the M<sub>4</sub> ACh concentration response curve (CRC), possesses an EC<sub>50</sub> value in the 400 nM range and causes no activation of the other mAChR subtypes. Additional *in vitro* pharmacological characterization studies suggested that VU10010 binds to an allosteric site on the M<sub>4</sub> receptor to increase affinity for ACh and coupling to G proteins (Shirey et al., 2008). Subsequent studies with VU10010 revealed that selective potentiation of M<sub>4</sub> increased carbachol (CCh)-induced depression at excitatory, but not inhibitory, synapses and that the effect on excitatory currents was not mimicked by an inactive analog of VU10010 or in M<sub>4</sub> knock-out mice (Shirey et al., 2008).

Despite this notable advance, VU10010 suffered from poor physiochemical properties (logP~4.5) and *in vivo* studies proved infeasible because we were unable to formulate VU10010 into a homogeneous solution in any acceptable vehicle, regardless of salt form or particle size. Several suspensions were prepared and dosed *i.p.*, but VU10010 was not found to be centrally active. In order to evaluate the role of selective M<sub>4</sub> activation *in vivo*, VU10010 would require further chemical optimization. Here we report the development and characterization of two novel analogs of VU10010 that are CNS penetrant following systemic administration.

JPET #140350

## Methods

**Materials.** All tissue culture reagents, as well as fluo-4 AM and BTC-AM, were obtained from Invitrogen (Carlsbad, CA). Acetylcholine chloride (ACh), Probenecid, Pluronic F-127, and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich, Inc., (St. Louis, MO). Costar 96-well cell culture plates (Cat # 3603), and V-bottom compound plates (Cat # 3897) were purchased from Corning Inc. (Corning, NY). 96-well Poly-D-Lysine coated assay plates (Cat # 356640) were purchased from Becton Dickinson (Bedford, MA). *l*-[N-methyl-<sup>3</sup>H]scopolamine methyl chloride (TRK666) was purchased from GE Healthcare (Little Chalfont, Buckinghamshire, UK).

**General Medicinal Chemistry Methods.** All NMR spectra were recorded on a 400 MHz Bruker NMR. <sup>1</sup>H chemical shifts are reported in  $\delta$  values in ppm downfield from TMS as the internal standard in DMSO. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). <sup>13</sup>C chemical shifts are reported in  $\delta$  values in ppm with the DMSO carbon peak set to 39.5 ppm. Low resolution mass spectra were obtained on an Agilent 1200 LCMS with electrospray ionization. High resolution mass spectra were recorded on a Waters QToF-API-US plus Acquity system. Analytical thin layer chromatography was performed on 250  $\mu$ m silica gel 60 F<sub>254</sub> plates. Analytical HPLC was performed on an Agilent 1200 analytical LCMS with UV detection at 214 nm and 254 nm along with ELSD detection. Preparative purification was performed on a custom Agilent 1200 preparative LCMS with collection triggered by mass detection. Solvents for extraction, washing and chromatography were HPLC grade. All reagents were purchased from Aldrich Chemical Co., Maybridge, ChemBridge and SPECS and were used without purification. All polymer-supported reagents were purchased from Biotage, Inc.

**General Procedure for Library Synthesis of Analogs 7.** Each of thirty-one glass vials containing 3 mL of CH<sub>2</sub>Cl<sub>2</sub> were loaded with *N,N*-diisopropylethylamine (0.3 mL, 1.70 mmol), 3-amino-4,6-

JPET #140350

dimethylthioenol[2,3-*b*]-pyridine-2-carboxylic acid (50 mg, 0.225 mmol, SPECS AM-807/25050004), 1-hydroxybenzotriazole hydrate (30.4 mg, 0.225 mmol, 1.0 equivalents), polystyrene-bound *N*-cyclohexylcarbodiimide (317 mg, 0.450 mmol, 1.42 mmol/g, 2.0 equivalents), and one of thirty-one amines (0.225 mmol, 1.0 equivalents). The reactions were stirred for 48 hours at room temperature. Next, macroporous triethylammonium methylpolystyrene carbonate (145 mg, 0.225 mmol, 3.11 mmol/g, 2.0 equivalents) was added, and the reactions were stirred for an additional 3 hours at room temperature. Then, the reactions were filtered and concentrated on a heat-air block to afford 84-99% pure products. Those <99% pure were purified by mass-directed HPLC.

**3-amino-*N*-(benzo[*d*][1,3]dioxol-5-ylmethyl)-4,6-dimethylthieno[2,3-*b*]pyridine carboxamide (VU0152099).** To a stirred solution of 3-amino-4,6-dimethylthioenol[2,3-*b*]-pyridine-2-carboxylic acid (3.0 g, 13.51 mmol [Chembridge cat.# 4003557]) in CH<sub>2</sub>Cl<sub>2</sub> (90 mL) was added *N,N*-diisopropylethylamine (10 mL, 56.66 mmol), 1-hydroxybenzotriazole hydrate (1.83 g, 13.51 mmol, 1.0 equivalents), 4-methoxybenzylamine (2.04 g, 14.86 mmol, 1.1 equivalents), and *N*-(3-dimethylaminopropyl)-*N'*-ethyl-carbodiimide hydrochloride (5.18 g, 27.02 mmol, 2.0 equivalents) at 25°C under room atmosphere. After 48 hours, macroporous triethylammonium methylpolystyrene carbonate (4.4 g, 13.51 mmol, 3.077 mmol/g, 1.0 equivalents) was added to the solution, which was then stirred for 3 hours at 25°C under room atmosphere. Next, the solution was vacuum filtered and the filtrate was separated with citric acid (1.0 M in water) and CH<sub>2</sub>Cl<sub>2</sub>. The organics were dried over MgSO<sub>4</sub> and concentrated *in vacuo* to produce a dark yellow solid. The solid was purified by column chromatography (silica gel, fixed 1:2 EtOAc:hexanes) to afford 2.5 g (7.33 mmol, 54%) of the title compound as a bright yellow solid. Analytical LC/MS (J-Sphere80-S4, 3.0 x 50 mm, 4.0 min gradient, 5% [CH<sub>3</sub>CN]:95% [0.1% TFA/H<sub>2</sub>O] to 100% [CH<sub>3</sub>CN]): 2.773 min, >99% (214 nm and ELSD), M+1 peak *m/e* 342.12; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 7.27 (d, *J* = 8.8 Hz, 2H), 6.89 (s, 1H), 6.86 (d, *J* = 8.8 Hz, 2H), 6.34 (br s, 2H), 5.80 (s, 1H), 4.53 (d, *J* = 6.0 Hz, 2H), 3.79 (s, 3H), 2.73 (s, 3H), 2.57 (s, 3H); <sup>13</sup>C

JPET #140350

NMR (100 MHz, DMSO- $d_6$ )  $\delta$  165.9, 159.3, 159.2, 147.7, 143.9, 130.7, 129.3, 123.7, 122.4, 114.4, 98.5, 55.5, 43.3, 24.5, 20.4; HRMS (Q-ToF):  $m/z$  calc for  $C_{18}H_{19}N_3O_2S$  [M + H]: 342.1198; found, 342.1276.

**3-amino-*N*-(4-methoxybenzyl)-4,6-dimethylthieno[2,3-*b*]pyridine carboxamide (VU0152100).** To a stirred solution of 3-amino-4,6-dimethylthienol[2,3-*b*]-pyridine-2-carboxylic acid (2.50 g, 11.26 mmol [Chembridge cat.# 4003557]) in  $CH_2Cl_2$  (90 mL) was added *N,N*-diisopropylethylamine (10 mL, 56.66 mmol), 1-hydroxybenzotriazole hydrate (1.52 g, 11.26 mmol, 1.0 equivalents), piperonylamine (1.87 g, 12.38 mmol, 1.1 equivalents), and *N*-(3-dimethylaminopropyl)-*N'*-ethyl-carbodiimide hydrochloride (4.32 g, 22.52 mmol, 2 equivalents) at 25°C under room atmosphere. After 48 hours, macroporous triethylammonium methylpolystyrene carbonate (3.66 g, 11.26 mmol, 3.077 mmol/g, 1.0 equivalents) was added to the solution, which was then stirred for 3 hours at 25°C under room atmosphere. Next, the solution was vacuum filtered and the filtrate was separated with citric acid (1.0 M in water) and  $CH_2Cl_2$ . The organics were dried over  $MgSO_4$  and concentrated *in vacuo* to produce a dark yellow solid. The solid was purified by column chromatography (silica gel, fixed 1:2 EtOAc:hexanes) to afford 2.0 g (5.63 mmol, 50%) of the title compound as a yellow solid. Analytical LC/MS (J-Sphere80-S4, 3.0 x 50 mm, 4.0 min gradient, 5%[ $CH_3CN$ ]:95% [0.1% TFA/ $H_2O$ ] to 100%[ $CH_3CN$ ]): 2.740 min, >99% (214 nm and ELSD), M+1 peak  $m/e$  356.10;  $^1H$  NMR (400 MHz, DMSO- $d_6$ )  $\delta$  8.38 (s, 1H), 7.18 (s, 1H), 6.88 (s, 1H), 6.84 (d,  $J = 8.0$  Hz, 1H), 6.78 (d,  $J = 8.0$  Hz, 1H), 5.98 (br s, 2H), 5.97 (s, 2H), 4.30 (d,  $J = 5.2$  Hz, 2H), 2.77 (s, 3H), 2.57 (s, 3H);  $^{13}C$  NMR (100 MHz, DMSO- $d_6$ )  $\delta$  179.9, 164.8, 161.7, 158.0, 153.4, 147.4, 133.8, 122.4, 121.9, 120.5, 108.0, 107.9, 100.8, 92.8, 42.1, 22.4, 20.0; HRMS (Q-ToF):  $m/z$  calc for  $C_{18}H_{17}N_3O_3S$  [M + H]: 356.0991; found, 356.1069.

**Cell Culture.** Chinese hamster ovary (CHO-K1) cells stably expressing rat (r)  $M_1$  were purchased from the American Type Culture Collection (ATCC) and cultured according to their recommendations. CHO cells stably expressing human (h)  $M_2$ , h $M_3$ , and h $M_5$  were generously provided by A. Levey (Emory



JPET #140350

University, Atlanta, GA); rM4 cDNA provided by T.I. Bonner (National Institutes of Health, Bethesda, MD) was used to stably transfect CHO-K1 cells purchased from the ATCC using Lipofectamine 2000. To make stable hM<sub>2</sub> and rM<sub>4</sub> cell lines for use in calcium mobilization assays, cell lines were cotransfected with a chimeric G protein (G<sub>qi5</sub>) using Lipofectamine 2000. rM<sub>2</sub>, hM<sub>3</sub>, and hM<sub>5</sub> cells were grown in Ham's F-12 medium containing 10% heat-inactivated fetal bovine serum (FBS), 2 mM GlutaMax I, 20 mM HEPES, and 50 µg/ml G418 sulfate. hM<sub>2</sub>-G<sub>qi5</sub> cells were grown in the same medium supplemented with 500 µg/ml Hygromycin B. Stable rM<sub>4</sub> cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated FBS, 2 mM GlutaMax I, 1 mM sodium pyruvate, 0.1mM nonessential amino acids, 20 mM HEPES, and 400 µg/ml G418 sulfate; rM<sub>4</sub>-G<sub>qi5</sub> cells were grown in the same medium supplemented with 500 µg/ml Hygromycin B.

CHO cells stably expressing rM<sub>1</sub>, hM<sub>3</sub>, or hM<sub>5</sub> were plated at a seeding density of 50,000 cells/100µl/well. CHO cells stably co-expressing hM<sub>2</sub>/G<sub>qi5</sub> and rat M<sub>4</sub>/G<sub>qi5</sub> were plated at a seeding density of 60,000 cells/100µl/well. HEK/GIRK cells stably expressing the human M<sub>4</sub> receptor were grown as described in (Niswender et al., 2008) and plated at 60,000 cells/100µl/well. For calcium mobilization or GIRK-mediated thallium flux assays, cells were incubated in antibiotic-free medium overnight at 37°C/5% CO<sub>2</sub> and assayed the following day.

**Calcium mobilization assay.** Cells were loaded with calcium indicator dye [2µM Fluo-4 AM, (50µl/well) prepared as a stock in DMSO and mixed in a 1:1 ratio with 10% Pluronic acid F-127 in assay buffer (1X Hanks' Balanced Salt Solution (HBSS) supplemented with 20mM HEPES and 2.5 mM probenecid, pH 7.4)] for 45 min at 37°C. Dye was removed and replaced with the appropriate volume of assay buffer. All compounds were serially diluted in assay buffer for a final 2X stock in 0.6% DMSO. This stock was then added to the assay plate for a final DMSO concentration of 0.3%. Acetylcholine (EC<sub>20</sub> concentration or full dose-response curve) was prepared at a 10X stock solution in assay buffer

JPET #140350

prior to addition to assay plates. Calcium mobilization was measured at 25°C using a FLEXstation II (Molecular Devices, Sunnyvale, CA).

Cells were preincubated with test compound (or vehicle) for 1.5 min prior to the addition of the agonist, acetylcholine. Cells were then stimulated for 50 sec with a submaximal concentration (EC<sub>20</sub>) or a full dose-response curve of acetylcholine. The signal amplitude was first normalized to baseline and then as a percentage of the maximal response to acetylcholine.

**GIRK-mediated Thallium Flux assay:** Cells were incubated with 80µL/well of 1.7µM BTC-AM indicator dye [prepared as a stock in DMSO and mixed in a 1:1 ratio with 10% Pluronic acid F-127 in assay buffer (1X HBSS supplemented with 20mM HEPES)] for 1 hour at room temperature in the dark. The dye was then replaced with 40µL of assay buffer. Test compounds were prepared as described above. Acetylcholine (EC<sub>20</sub> concentration or full dose-response curve) was prepared as a 5X stock solution in thallium buffer (pH 7.3, 12mM thallium sulfate, 1mM MgSO<sub>4</sub>, 1.8mM CaSO<sub>4</sub>, 5mM glucose, 10mM HEPES) to which 125mM NaHCO<sub>3</sub> was added immediately before use. Thallium flux was measured at 25°C using the FLEXstation II, as described above for calcium mobilization assays. The slope of the fluorescence increase was obtained over a 10 sec window beginning at 5 sec after agonist/thallium addition. The signal amplitude was first normalized to baseline and then as a percentage of the maximal response to acetylcholine.

**Radioligand Binding studies:** All binding reactions were carried out essentially as described in (Shirey et al., 2008) using 25µg of membrane protein prepared from rM4 expressing CHO cells and 0.1nM [<sup>3</sup>H]-NMS (GE Healthcare) in a final volume of 1mL. Non-specific binding was determined in the presence of 1µM atropine.

JPET #140350

**Ancillary Pharmacology Assays.** Prior to conducting *in vivo* experiments, VU0152099 and VU0152100 were submitted to MDS Pharma ([www.mdsp.com](http://www.mdsp.com)) and evaluated in the LeadProfiling Screen®, a radioligand binding assay panel employing 68 GPCRs, ion channels, transporters and enzymes, to ensure a clean ancillary pharmacology profile. VU0152099 also was submitted to Millipore's GPCR Profiler™ Service where it was evaluated for agonist, antagonist, and allosteric potentiator activity against a panel of 16 GPCRs in a functional screening paradigm.

**JetMilling.** Both VU0152099 and VU0152100 were JetMilled, to afford uniform nanoparticles, prior to vehicle formulation and *in vivo* studies employing a Model 00 Jet-O-Mizer with a High-Yield® Collection Module from Fluid Energy Processing & Equipment Company (see: [www.fluidenergype.com](http://www.fluidenergype.com)).

### ***In vivo* pharmacokinetic profiling and behavioral studies**

All experiments were conducted in accordance with the National Institutes of Health regulations of animal care covered in Principles of Laboratory Animal Care (National Institutes of Health publication 85-23, revised 1985) and were approved by the Institutional Animal Care and Use Committee.

### **Amphetamine-induced hyperlocomotion:**

*Animals.* All behavioral studies were conducted using male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc.; Indianapolis, IN) weighing 270 to 300 grams. Subjects were housed in pairs in a large colony room under a 12-h light/dark cycle (lights on at 6:00 a.m.) with food and water provided *ad libitum*. Test sessions were performed between 6:00 a.m. and 6:00 p.m. Dose groups consisted of 8-16 rats per dose group. All doses of VU0152099 and VU0152100 refer to the salt form and were injected in a 1.0 ml/kg volume. Each compound was dissolved in 10% Tween 80 and double deionized water with the pH adjusted to approximately 7.0 using 1N NaOH.

*Apparatus:* Amphetamine-induced hyperlocomotor activity studies were conducted using a SmartFrame Open Field System (Kinder Scientific., San Diego, CA) equipped with 32 horizontal (x- and

JPET #140350

y-axes) infrared photobeams located 1 cm above the floor of the chamber. Changes in ambulation or locomotor activity were measured as the number of total photobeam breaks, expressed in 5 min intervals, and were recorded with a Pentium I computer equipped with the Motor Monitor System software (Kinder Scientific).

*Procedure:* Rats were placed in the open field chambers for a 30 min habituation interval (data not shown), followed by a pretreatment with vehicle or a 56.6 mg/kg dose of either VU0152099 or VU0152100 *i.p.* for an additional 30 min. Next, all rats received an injection of 1 mg/kg *s.c.* of amphetamine and locomotor activity was measured for an additional 60 min. Data were analyzed by a one-way ANOVA with comparison with the vehicle+amphetamine control group using Dunnett's test. Calculations were performed using JMP v5.1.2 (SAS Institute Inc., Cary, NC) statistical software.

#### **Rotorod Test:**

The effects of VU0152100 on motor performance were evaluated using a Rotorod (Columbus Instruments, Columbus, OH). All rats were given an initial training trial of 120 sec, followed by 2 additional training trials of 85 sec, approximately 10 min apart, using a rotarod (7.5cm in diameter) rotating at a constant speed of 20 revolutions/min. After initial training trials, a baseline trial of 85 sec was conducted and any rats that did not reach the 85 sec criteria were excluded from the study. Rats were then pretreated for 30 min *i.p.* with vehicle or dose of VU0152100, specifically 30, 56.6 or 100 mg/kg, and then the time each animal remained on the rotorod was recorded; animals not falling off the rotorod were given a maximum score of 85 sec. Data were analyzed by a one-way ANOVA, with comparison to the vehicle control group using Dunnett's test. Calculations were performed using JMP v5.1.2 (SAS Institute Inc., Cary, NC) statistical software.

#### **Brain and plasma exposure pharmacokinetic profiling:**

Male Sprague-Dawley rats (Harlan Sprague-Dawley, Inc.; Indianapolis, IN) weighing 225-250g, were fasted overnight prior to dosing. Compounds were dissolved at a concentration of 56.6 mg/mL in 10% Tween 80 and double deionized water, with the pH adjusted to approximately 7.0 using 1N NaOH,

JPET #140350

and sonicated until a uniform homogenous solution was obtained. The dose was administered *i.p.* at 56.6 mg/kg per compound. Three animals were used for each time point. The rat blood and brain were collected at 0.5, 1, 2, and 4h. Animals were euthanized, decapitated and the brains removed and frozen on dry ice. Trunk blood was collected in EDTA Vacutainer tubes and plasma was separated by centrifugation and stored at -80 °C until analysis.

For the brain sample preparation, frozen whole rat brains were weighed (1.5 to 1.8g) and placed in 3 ml of ice-cold solution of acetonitrile and methanol (1:1, volume) with a synthetic internal standard (50 ng/mL) and homogenized using a Sonic Dismembrator Model 100 (Fischer Scientific) at maximal speed for 2 min. Next, a 1ml aliquot of each homogenate was placed into 1.5 ml centrifuge tubes and centrifuged at 16,000 rpm for 5 min. Finally 100 µl of supernatant was injected into LC-MS-MS.

Plasma samples (100µl) were combined with 200µl of ice-cold solution of the internal standard (100ng/ml) in acetonitrile with 0.1% formic acid. After vortexing for one minute, the mixture was centrifuged at 16,000 rpm for 5 min in a bench-top Spectrafuge 16M Microcentrifuge (Labnet, Woodbridge, NJ). Again, 100 µl of the supernatant was injected into LC-MS-MS.

For the LC-MS-MS Analysis, the LC separation was carried out on a Phenomenex Luna ODS, 5 micron, 2.1 mm x 5 cm column (Torrance, CA) at a flow rate of 0.3 ml/min. The gradient started with 80% solvent A (0.1% Formic acid in water) and 20% solvent B (0.1% Formic acid in CH<sub>3</sub>CN), held for 1 min and increasing to 100% B in 4 min and held for 1 min. Mass spectrometry was carried out using a ThermoFinnigan TSQ Quantum ultra (Thermo Scientific, Waltham, MA) mass spectrometer in positive ion mode. The software Xcalibur version 2.0 was used to control the instrument and collect data. The ESI source was fitted with a stainless steel capillary (100µm i.d.). Nitrogen was used as both the sheath gas and the auxiliary gas. The ion transfer tube temperature was 300°C. The spray voltage, tube lens voltage, pressure of sheath gas and auxiliary gas were optimized to achieve maximal response using the test compounds mixing with the mobile phase A (50%) and B (50%) at a flow rate of 0.3 ml/min. Collision-induced dissociation (CID) was performed on the test compounds and internal standards under

JPET #140350

1.0 mTorr of argon. Selected reaction monitoring (SRM) was carried out using the transitions from, m/z 356 to 205 @ 30 eV for VU0152099, m/z 342 to 205 @ 27 eV for VU0152100, and m/z 310 to 223 @ 25 eV for our internal standard.

The calibration curves were constructed by spiking known amounts of test compounds in blank brain homogenates and plasma. The samples went through the same extraction steps as described above. A linear response was achieved from 50ng/ml to 100ug/ml in both matrices. Compound exposure following administration was determined by calculating AUC (0-∞) using the trapezoidal method.

JPET #140350

## Results

### Chemical Lead Optimization

For the chemical optimization of VU10010, we undertook a diversity-oriented synthesis (DOS) approach to explode Structure-Activity-Relationships (SAR) with a variety of hypothesis-driven, structural changes to the lead compound. The rationale for this approach for the optimization of VU10010 is that SAR for allosteric ligands is often ‘flat’ or ‘shallow’, with subtle structural modifications leading to a complete loss of activity, and often only one portion of an allosteric ligand is amenable to change. Therefore, a multi-dimensional, DOS library approach provides the best opportunity to quickly identify productive SAR as opposed to a lead optimization strategy based on classical, single compound synthesis (Lindsley et al., 2004; Zhao et al., 2007). One explanation for the lack of central activity observed with VU10010 could be the result of the poor physiochemical properties alone, or in combination with P-glycoprotein (P-gp) efflux. P-gp is an efflux transporter with broad substrate specificity present on the luminal membrane of epithelial cells comprising the blood-brain barrier, which is known to impair the brain penetrability of a number of drugs. The  $\beta$ -aminoamide motif 3 present in VU10010 represents a potential P-gp liability, which could be removed by cyclization to analogs such as 4 (Fig. 2A). Alternatively, P-gp susceptibility could also be diminished by electronically attenuating the basicity of the amine moieties by the incorporation of distal fluorine atoms. Utilizing solution phase parallel synthesis (Fig. 2B), we synthesized small, 12- to 24-member focused libraries around each of the 10 scaffolds 4, 7-15 (Fig. 2C) which were then purified by mass-directed preparative HPLC to analytical purity (>98%). This collection of VU10010 analogs incorporated CF<sub>3</sub> moieties (scaffolds 9 and 10) to electronically attenuate potential P-gp susceptibility, deletion of the  $\beta$ -amino moiety (scaffold 14), or replacement of the  $\beta$ -amino moiety with an isosteric methyl group (scaffold 13). Other scaffolds explored the deletion of substituents on the pyridine nucleus (scaffold 11), incorporation of an additional nitrogen atom to afford a pyrimidine nucleus (scaffold 12) or removal of the pyridine nitrogen atom in VU10010

JPET #140350

(scaffold 15). Finally, scaffold 7 focused on maintaining the core structure of VU10010, but explored alternative amides, selected to improve physiochemical properties and lower the logP value.

### Screening Paradigm for Analog Libraries

As observed with positive allosteric modulators of Class C GPCRs, SAR around VU10010 was relatively flat, possibly due to a shallow binding pocket (Lindsley et al., 2004; Zhao et al., 2007). An EC<sub>20</sub> triage screen, employing a functional fluorescence-based Ca<sup>2+</sup> assay in CHO K1 cells stably co-expressing the rat M<sub>4</sub> mAChR and the chimeric G protein, G<sub>qi5</sub>, quickly eliminated all VU10010 analogs except those in library 7 (built around scaffold 7) (Fig. 3). Within library 7, all aliphatic and non-benzyl amides were inactive, and only benzyl and heteroaryl methyl congeners of VU10010, 7a-7p, retained M<sub>4</sub> PAM activity (Table 1). Analogs were synthesized as described previously (Shirey et al., 2008). To identify compounds that potentiated agonist activation of M<sub>4</sub>, we determined the response to an EC<sub>20</sub> concentration of ACh in the absence and presence of test compound. The potency of each compound was determined by pre-incubating cells with vehicle or increasing concentrations of test compound followed by the addition of an EC<sub>20</sub> concentration of ACh to yield concentration-response curves (CRCs). Subtle substitution changes on the arene ring lost activity 5-10-fold in terms of M<sub>4</sub> EC<sub>50</sub> and/or fold-shift of the ACh CRC (Table 1). For instance, 7d, in which the 4-Cl moiety of VU10010 is moved to the 3-position results in a loss in potency of over 9-fold (EC<sub>50</sub> = 3.7 μM). Similarly, the unsubstituted phenyl congener 7a retains M<sub>4</sub> PAM activity (EC<sub>50</sub> = 630 nM), but the fold-shift diminishes to 8.6-fold, *versus* the 47-fold shift observed for VU10010 (Shirey et al., 2008). In general, functionalized benzyl amides, as well as pyridyl methyl congeners (7f and 7g), were well tolerated, providing selective M<sub>4</sub> PAMs with EC<sub>50</sub> values ranging from 380 nM to 3.7 μM and with fold-shifts of the ACh dose-response curve from 8.6- to 70-fold.

**VU0152099 and VU0152100 are Potent Positive Allosteric Modulators of M<sub>4</sub> in two independent *in vitro* assays.**



JPET #140350

Two compounds were selected for further evaluation of their ability to potentiate the  $M_4$ -mediated calcium response. VU0152099 (7o), (Fig. 4A) and VU0152100 (7p), (Fig. 4D) retained  $M_4$  PAM activity ( $EC_{50}$  values of  $403 \pm 117$  nM and  $380 \pm 93$  nM, respectively) comparable to VU10010, and in the absence of an ACh  $EC_{20}$ , neither VU0152099 nor VU0152100 elicited a response (Fig. 4B, E). We next determined the effects of maximal concentrations of each compound on the CRC of ACh. Cells were pre-incubated with a fixed concentration (0.1-30  $\mu$ M) of test compound and subsequently stimulated with increasing concentrations of ACh. Both VU0152099 and VU0152100 induced a dose-dependent leftward shift of the ACh CRC with maximal shifts of 30-fold observed with 30  $\mu$ M VU0152099 (Fig. 4C) and 70-fold observed with 10  $\mu$ M VU0152100 (Fig. 4F).

Using calcium mobilization to assess the functional activity of VU0152099 and VU0152100 at the  $M_4$  receptor requires co-expression of the chimeric G protein,  $G_{q15}$ , in order to link the  $G_{i/o}$ -coupled  $M_4$  receptor to the PLC $\beta$ /Ca<sup>2+</sup> pathway. As an alternative approach to measure  $M_4$  PAM activity, we chose to take advantage of a novel functional assay recently developed in our lab that takes advantage of the ability of endogenous  $G_{\beta\gamma}$  subunits of  $G_{i/o}$ -coupled GPCRs to alter the kinetics of G-protein regulated inwardly rectifying K<sup>+</sup> (GIRK) channels to conduct the ion, thallium (Niswender et al., 2008). For these studies, HEK293 cells stably co-expressing heteromeric GIRK1/2 channels and the human  $M_4$  muscarinic receptor were pre-incubated with test compound and then stimulated with agonist (ACh) in the presence of thallium ion. Both VU0152099 and VU0152100 dose-dependently potentiated the response to an  $EC_{20}$  concentration of ACh with  $EC_{50}$  values of  $1.2 \pm 0.3$   $\mu$ M and  $1.9 \pm 0.2$   $\mu$ M, respectively, and increased the maximal response to ACh to approximately 130 % (Fig 5A). As observed in the calcium mobilization assays described above, both VU0152099 and VU0152100 (10  $\mu$ M) also enhanced the potency of ACh to induce GIRK-mediated thallium flux, as manifest by a robust ( $\approx$ 30-fold) leftward shift in the ACh CRC from  $77 \pm 1.2$  nM (veh) to  $2.09 \pm 0.3$  nM (VU0152099) and  $2.35 \pm 0.5$  nM (VU0152100) (Fig 5B). Taken together, these *in vitro* studies suggest that VU0152099 and VU0152100 are potent positive allosteric modulators that enhance the response of the  $M_4$  receptor to the endogenous agonist, ACh.

JPET #140350

### **VU0152099 and VU0152100 bind to an allosteric site on the M<sub>4</sub> receptor and increase ACh affinity**

To further confirm an allosteric mechanism of action by the novel M<sub>4</sub> PAMs, we evaluated the effect of VU0152099 and VU0152100 on equilibrium radioligand binding using membranes prepared from cells expressing the rM<sub>4</sub> receptor. We first assessed the ability of increasing concentrations of the two M<sub>4</sub> PAMs to displace the orthosteric radioligand, [<sup>3</sup>H]-NMS (0.1nM). Unlike the orthosteric antagonist, atropine, which potently inhibited [<sup>3</sup>H]-NMS binding ( $K_i = 0.54 \pm 0.1\text{nM}$ ), neither M<sub>4</sub> PAM displaced [<sup>3</sup>H]-NMS at concentrations up to 30 $\mu\text{M}$  (Fig. 6A), strongly suggesting that VU0152099 and VU0152100 act at a site on the M<sub>4</sub> receptor that is distinct from the orthosteric binding site.

In addition, we evaluated the effect of VU0152099 and VU0152100 on the affinity of ACh for the M<sub>4</sub> receptor by assessing the ability of an increasing concentration of ACh to displace [<sup>3</sup>H]-NMS (0.1nM) binding in the absence or presence of the M<sub>4</sub> potentiators. VU0152099 and VU0152100 were found to induce a 20-25 fold leftward shift in the potency of ACh to displace [<sup>3</sup>H]-NMS binding to M<sub>4</sub>, as manifest by a reduction in the ACh  $K_i$  from  $252 \pm 17.9\text{ nM}$  (veh) to  $10.4 \pm 0.91\text{ nM}$  (VU0152099) and  $12.2 \pm 0.49\text{ nM}$  (VU0152100) (Fig. 6B). These data present a possible mechanism whereby these compounds could enhance receptor activation by increasing the affinity of M<sub>4</sub> for acetylcholine, and are in agreement with data previously determined for VU10010, where a 14 fold decrease in the ACh  $K_i$  was reported (Shirey et al., 2008).

### **VU0152099 and VU0152100 are Selective for the M<sub>4</sub> mAChR subtype**

We next evaluated VU0152099 and VU0152100 in calcium mobilization assays for effects at all mAChR subtypes to determine whether these compounds are selective for M<sub>4</sub>. Both VU0152099 and VU0152100 were selective for M<sub>4</sub> relative to M<sub>1</sub>, M<sub>2</sub>, M<sub>3</sub> and M<sub>5</sub>. Thus, neither VU0152099 (Fig. 7A) nor VU0152100 (Fig. 7B) had any effect on the ACh dose-response curves at these other mAChR subtypes at concentrations up to 30  $\mu\text{M}$ . To further assess selectivity of these compounds for M<sub>4</sub> relative to other potential targets, the activity of VU0152099 and VU0152100 also were evaluated in radioligand binding

JPET #140350

assays against a large panel of 68 discrete GPCRs, ion channels, transporters and enzymes (see Supplemental Table 1). These compounds were largely inactive at each of the targets in this panel screen. At concentrations of 10 $\mu$ M, both compounds were completely inactive at most targets and induced less than 50% displacement of binding for all targets tested, with the single exception of GABA<sub>A</sub> receptors (assessed by flunitrazepam binding), where VU0152099 displayed 51% displacement. This suggests that VU0152099 may interact with the flunitrazepam site with an IC<sub>50</sub> value of approximately 10 $\mu$ M, which still provides high selectivity for M<sub>4</sub> relative to GABA<sub>A</sub> receptors.

Since VU0152099 and VU0152100 are allosteric modulators of M<sub>4</sub>, it is possible that they have activity at similar allosteric sites on other GPCRs. If so, this would not be apparent in the radioligand binding assays discussed above. The finding that these compounds are completely inactive at other mAChR subtypes makes this less likely since M<sub>4</sub> is more closely related to the other mAChR subtypes than to other GPCRs. However, to further evaluate the selectivity of VU0152099 for M<sub>4</sub> relative to other family A GPCRs, we contracted with Millipore Corp. (St. Charles, MO) to determine the effects of this compound on the functional response of a panel of 16 GPCRs (including human M<sub>4</sub>) to activation by their respective agonists. For these studies, we chose family A GPCR subtypes that are among the closest relatives of mAChRs. We first determined the effects of VU0152099 alone on each receptor and found that these compounds had no agonist activity at any receptor studied (data not shown). We then determined the effects of VU0152099 on full concentration response curves of agonists of each of these receptors. This allows unambiguous evaluation of whether the compounds possess antagonist activity (either allosteric or orthosteric) or allosteric potentiator activity at these other GPCRs. Consistent with our internal studies, VU0152099 induced a robust potentiation of ACh-induced activation of human M<sub>4</sub>, but had no potentiator activity at M<sub>1</sub> (Supplemental Figure 1). In addition, VU0152099 had no allosteric potentiator activity at any of the other GPCR subtypes tested (Supplemental Figure 1). The only significant activity detected for VU0152099 in this functional panel screen was weak antagonist activity at the serotonin 5HT<sub>2B</sub> receptor (Supplemental Figure 1). Together, these data suggest that VU0152099

JPET #140350

and VU0152100 possess clean ancillary pharmacology profiles, which would allow us to pursue the behavioral effects of selective M<sub>4</sub> activation *in vivo*.

### **VU0152099 and VU0152100 Exhibit Improved Physiochemical and Pharmacokinetic Properties**

Prior to conducting *in vivo* studies with VU0152099 and VU0152100, pharmacokinetic studies were undertaken to assess brain/plasma ratios following systemic dosing of these compounds. In contrast, to the high logP of VU10010 (4.5), both VU0152099 and VU0152100 possessed logP values of 3.65 and 3.6, respectively, a full order of magnitude less lipophilic than VU10010 (Shirey et al., 2008). As a consequence, both VU0152099 and VU0152100 displayed improved physiochemical properties and afforded homogeneous dosing solutions in multiple vehicles acceptable for *in vivo* studies. Further, we conducted *in vivo* exposure (brain and plasma) studies in rats at the dose of 56.6 mg/kg, *i.p.* Both compounds exhibited substantial systemic absorption and brain penetration (Fig. 8). After 56.6 mg/kg *i.p.* administration, peak brain concentrations for both of the compounds were in the range of 3-5 µg/ml. VU0152100 (Fig. 8B) was far superior to VU0152099 (Fig. 8A) in terms of brain penetration, as evident from AUC (0-∞) values (Table 2). AUC brain/ AUC plasma ratio for VU0152099 was calculated to be 0.39±0.01, while the ratio for VU0152100 was determined to be 0.86±0.08 (Table 2). The half life of the compounds in brain was 1.25±0.02 h (VU0152099) and 1.12±0.01 h (VU0152100) (Table 2). Therefore, our earlier concern of P-gp susceptibility within this series was likely unwarranted, and the lack of central activity for VU10010 was most likely due solely to physiochemical properties.

### **VU0152099 and VU0152100 exhibit *in vivo* activity in rat**

Previous studies using the M<sub>1</sub>/M<sub>4</sub>-preferring muscarinic agonist xanomeline produced robust effects in several preclinical models predictive of antipsychotic-like activity, including reversal of amphetamine-induced hyperlocomotion in rats (Stanhope et al., 2001). Based on our initial pharmacokinetic studies suggesting that systemic administration of VU0152099 and VU0152100 provides robust brain levels of these compounds, the effects of VU0152099 and VU0152100 were

JPET #140350

evaluated in reversing amphetamine-induced hyperlocomotion in rats using a dose of 56.6 mg/kg *i.p.* for each compound with a 30 min pretreatment interval. As shown in Fig. 9A, both VU0152099 and VU0152100 produced robust decreases in amphetamine-induced hyperlocomotion over the time course tested. In addition, to provide further confirmation that the M<sub>4</sub> PAMs have no effect on baseline levels of motor performance, which could complicate the interpretation of the amphetamine-induced hyperlocomotion data, we evaluated the effects of one of the M<sub>4</sub> PAMs, specifically VU0152100, after administration alone on performance in the rotorod test (Fig. 9B). As shown, VU0152100 had no effect on performance in the rotorod test, even when tested at a dose of 100mg/kg, which was higher than that required to observe reversal of amphetamine-induced hyperlocomotion.

JPET #140350

## Discussion

For decades, the prevailing theory behind the etiology of schizophrenia has been that excessive dopaminergic neurotransmission in the central nervous system is the major contributing factor underlying this severe psychiatric illness. This so-called dopamine hyperfunction hypothesis is based primarily on the observation that stimulation of the endogenous dopamine system (*e.g.* with amphetamine or cocaine) often leads to transient psychotic symptoms in healthy individuals (Bymaster et al., 2002; Raedler et al., 2007). Furthermore, all clinically relevant antipsychotic drugs, both typical and atypical, possess significant antagonist activity at D<sub>2</sub> dopamine receptors (D<sub>2</sub>Rs) (Carlsson, 1988; Bymaster et al., 2002; Raedler et al., 2007). Thus, the majority of efforts to discover novel therapeutic agents for the treatment of schizophrenia have been aimed at developing therapies that result in some level of D<sub>2</sub>R blockade or a combination of blockade of D<sub>2</sub>Rs and other monoamine receptors. Nevertheless, D<sub>2</sub>R antagonists are only partially effective in treating schizophrenia, in that they only improve the positive symptoms associated with the disease, despite the fact that the negative and cognitive symptoms also markedly impact the quality of life for schizophrenic patients. In addition, these therapies also are often poorly tolerated because of numerous side effects including sedation, weight gain, sexual dysfunction, diabetes and Parkinson's disease-like symptoms. Furthermore, greater than 25% of schizophrenia patients do not respond to these dopamine-based therapies (Hirsch and Barnes, 1995). Thus, while it is evident that dopamine does play a prominent role in the pathogenesis and treatment of schizophrenia, the dopamine hyperfunction hypothesis of schizophrenia fails to account for all aspects of this disorder and it is increasingly evident that other neurotransmitter systems are likely involved. Based on this, it is unlikely that exclusive focus on discovery and development of antagonists of D<sub>2</sub>Rs and other monoamine receptors will provide fundamental breakthroughs in the standard of treatment of schizophrenia patients relative to current therapies.

In recent years, the mAChRs have emerged as potential novel targets for the treatment of schizophrenia. This is based on clinical studies demonstrating efficacy of mAChR agonists in treatment of positive symptoms in schizophrenia patients, as well as multiple animal studies suggesting that

JPET #140350

mAChR agonists could be useful in treatment of cognitive dysfunction in schizophrenia patients (Bymaster et al., 2002). Furthermore, a growing body of evidence from clinical and animal studies involving pharmacological manipulations, post mortem tissue analysis, and brain imaging is consistent with this hypothesis (Raedler et al., 2007). While recent advances suggesting potential utility of mAChR activators in treatment of schizophrenia have been exciting, there have been few selective pharmacological tools available to fully explore this emerging muscarinic hypothesis of schizophrenia. Unfortunately, previous attempts to develop traditional orthosteric agonists that are highly selective for individual mAChR subtypes have been unsuccessful.

The current discovery and optimization of VU0152099 and VU0152100 as highly selective positive allosteric modulators of  $M_4$  provides a major advance in establishing a new approach for developing highly selective activators of these receptors. The data presented provide further support for the ability to achieve high subtype selectivity by targeting allosteric sites and provide exciting new data demonstrating that highly selective  $M_4$  PAMs have robust activity in at least one animal model that is similar to effects previously described for the non-selective orthosteric mAChR agonist, xanomeline (Stanhope et al., 2001). The finding that VU0152099 and VU0152100 mimic effects of xanomeline in an animal model that has been used to predict antipsychotic activity of new compounds is especially exciting in light of clinical studies demonstrating the clinical efficacy of xanomeline in schizophrenia patients. This raises the exciting possibility that selective activation of  $M_4$  may provide a novel approach for the treatment of some symptoms associated with schizophrenia. Furthermore, the discovery of systemically active  $M_4$  PAMs suggests that this will be a viable approach for developing selective activators of  $M_1$  and other mAChR subtypes.

While the *in vitro* data for VU0152099 and VU0152100 indicate high pharmacologic selectivity for  $M_4$  relative to any other mAChR subtypes or closely related GPCRs, the possibility exists that the observed behavioral effects may be due to an off-target activity not yet identified. In future studies, it will be critical to further validate that the effects of VU0152099 and VU0152100 observed *in vivo* are mediated by activation of  $M_4$  using other tools, including structurally distinct  $M_4$  PAMs or selective  $M_4$

JPET #140350

antagonists, as they become available, and/or M<sub>4</sub> knockout mice. Unfortunately, studies in M<sub>4</sub> knockout mice will be complex since these mice display fundamentally different responses to psychomotor stimulants and compounds will need to be optimized for appropriate pharmacokinetic properties in mice. Also, several behavioral parameters are substantially altered in the M<sub>4</sub> knockout mice, including increases in baseline locomotor activity, altered responses to amphetamine, and altered dopamine release in the mesolimbic dopamine circuitry (Gomeza et al., 1999, 2001; Tzavara et al., 2004). These factors will complicate interpretation of studies with M<sub>4</sub> knockout mice. However, while it is not possible to definitively establish an exclusive role for M<sub>4</sub> in mediating the behavioral effects observed here, previous studies have established similar effects of structurally distinct mAChR agonists (Stanhope et al., 2001). This, coupled with the high selectivities of VU0152099 and VU0152100 for M<sub>4</sub> relative to any other mAChR subtype, suggests that M<sub>4</sub> is a likely candidate for mediating these effects. Also, extensive profiling of VU0152099 and VU0152100 showed no functional effects on responses to other closely related family A GPCRs and no significant off-target activity at any of 68 other GPCRs, ion channels, or enzymes. Thus, while it is impossible to entirely rule out unknown off-target activity, these compounds appear to be much more highly selective for the targeted receptor than is typical for most orthosteric GPCR ligands. As new tools become available for targeting M<sub>4</sub> and other mAChR subtypes, they will provide the means to develop a more complete understanding of the roles of each of the individual mAChR subtypes in regulating CNS function.

In addition to their potential relevance for schizophrenia, mAChRs also are thought to regulate motor function by exerting effects on dopaminergic transmission in the basal ganglia (Pisani et al., 2007; Raedler et al., 2007). For instance, multiple electrophysiology studies with M<sub>4</sub> knockout mice have led to the suggestion that activation of the M<sub>4</sub> mAChR may oppose some actions of dopaminergic neurons on striatal motor function (Calabresi et al., 1998; Sanchez-Lemus and Arias-Montano, 2006). Again, the lack of highly selective activators of M<sub>4</sub> has made it impossible to test this hypothesis directly. Also, previous studies with traditional M<sub>4</sub> agonists bypass the action of endogenous ACh in the basal ganglia and do not provide information about the effects of endogenous acetylcholine on motor activity. The



JPET #140350

finding that highly selective M<sub>4</sub> potentiators reverse amphetamine-induced hyperlocomotor activity in rats provides exciting new evidence in support of the hypothesis that endogenous ACh plays an important role in regulating dopaminergic control of motor function. Because these compounds do not activate M<sub>4</sub> directly, but selectively increase responses of M<sub>4</sub> to endogenous ACh, this provides direct evidence that this response can be modulated by endogenous ACh acting on M<sub>4</sub> receptors. In addition, this raises the possibility that selective M<sub>4</sub> modulators could provide a novel approach to treatment of other disorders involving altered dopaminergic function in the basal ganglia, including Parkinson's disease and dystonia.

In addition to suggesting the potential roles of M<sub>4</sub> *in vivo*, these data have important implications related to the molecular pharmacology of allosteric modulators of GPCRs. One of the most promising properties of allosteric modulators of GPCRs has been that it is often possible to achieve high selectivity for a targeted GPCR subtype relative to closely related family members (Marino et al., 2003; O'Brien et al., 2003; Kinney et al., 2005; Galici et al., 2006). However, discovery of these compounds also raises the question of whether allosteric modulators may have broad activity across other GPCRs by interacting at potentially promiscuous allosteric sites. The present finding that VU0152099 and VU0152100 had no major activities across multiple targets in a large panel radioligand binding screen was encouraging in suggesting the high selectivity of these compounds, but does not address this critical question. However, the finding that these compounds had no allosteric modulator activity across a panel of 15 other family A GPCR subtypes is exciting and suggests that they are not likely to have activity at a site that is shared across multiple GPCRs. While it is impossible to rule out activity at other unidentified targets that were not tested, these data suggest that it may be possible to achieve higher subtype selectivity across a range of receptors than has been possible with many orthosteric ligands.

JPET #140350

### **Acknowledgements**

The authors thank Drs. A. Levey (Emory University, Atlanta, GA) for stable mAChR cell lines (hM<sub>2</sub>, hM<sub>3</sub>, and hM<sub>5</sub>), T.I. Bonner (NIMH, Bethesda, MD) for the rM<sub>4</sub> cDNA construct, and B. Conklin (Gladstone Institute, UCSF, San Francisco, CA) for the chimeric G<sub>qi5</sub> construct. HEK293 cells stably expressing GIRK1, GIRK2 and the human M<sub>4</sub> receptor were generously provided by Drs. Huai Hu Chang and Lily Jan (University of California San Francisco, San Francisco, CA).

JPET #140350

## References

- Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ and Paul SM (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. *Archives of Neurology* **54**:465-473.
- Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, Nathanson NM, McKinzie DL and Felder CC (2003a) Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. *European Journal of Neuroscience* **17**:1403-1410.
- Bymaster FP, Felder C, Ahmed S and McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. *Current Drug Targets - Cns & Neurological Disorders* **1**:163-181.
- Bymaster FP, McKinzie DL, Felder CC and Wess J (2003b) Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. *Neurochemical Research* **28**:437-442.
- Calabresi P, Centonze D, Pisani A, Sancesario G, North RA and Bernardi G (1998) Muscarinic IPSPs in rat striatal cholinergic interneurons. *Journal of Physiology* **510**:421-427.
- Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. *Neuropsychopharmacology* **1**:179-186.
- Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomeza J, Wess J and McKinzie DL (2001) Elucidating the role of muscarinic receptors in psychosis. *Life Sciences* **68**:2605-2613.
- Galici R, Jones CK, Hemstapat K, Nong Y, Echemendia NG, Williams LC, de Paulis T and Conn PJ (2006) Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. *Journal of Pharmacology & Experimental Therapeutics* **318**:173-185.

JPET #140350

Gomez J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodtkin J, Shannon H, Xia B, Deng C and Wess J (1999) Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.[see comment]. *Proceedings of the National Academy of Sciences of the United States of America* **96**:10483-10488.

Gomez J, Zhang L, Kostenis E, Felder CC, Bymaster FP, Brodtkin J, Shannon H, Xia B, Duttaroy A, Deng CX and Wess J (2001) Generation and pharmacological analysis of M2 and M4 muscarinic receptor knockout mice. *Life Sci* **68**:2457-2466.

Hemstapat K, de Paulis T, Chen Y, Brady AE, Grover VK, Alagille D, Tamagnan GD and Conn PJ (2006) A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. *Mol Pharmacol* **70**:616-626.

Hirsch S and Barnes TRE (1995) In *Schizophrenia*, Eds.Hirsch and Weinberger, Blackwell Science: Oxford, UK: pp. 440-445.

Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ and Williams DL, Jr. (2005) A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. *Journal of Pharmacology & Experimental Therapeutics* **313**:199-206.

Lindsley CW, Wisnoski DD, Leister WH, O'Brien J A, Lemaire W, Williams DL, Jr., Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ and Huff JR (2004) Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo. *J Med Chem* **47**:5825-5828.

Marino MJ and Conn PJ (2006) Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. *Current Opinion in Pharmacology* **6**:98-102.

JPET #140350

Marino MJ, Williams DL, Jr., O'Brien JA, Valenti O, McDonald TP, Clements MK, Wang R, DiLella AG, Hess JF, Kinney GG and Conn PJ (2003) Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. *Proceedings of the National Academy of Sciences of the United States of America* **100**:13668-13673.

Messer WS, Jr. (2002) Cholinergic agonists and the treatment of Alzheimer's disease. *Current Topics in Medicinal Chemistry* **2**:353-358.

Niswender CM, Johnson KA, Luo Q, Ayala JE, Kim C, Conn PJ and Weaver CD (2008) A novel assay of Gi/o-linked G protein-coupled receptor coupling to potassium channels provides new insights into the pharmacology of the group III metabotropic glutamate receptors. *Molecular Pharmacology* **73**:1213-1224.

O'Brien JA, Lemaire W, Chen TB, Chang RS, Jacobson MA, Ha SN, Lindsley CW, Schaffhauser HJ, Sur C, Pettibone DJ, Conn PJ and Williams DL, Jr. (2003) A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. *Mol Pharmacol* **64**:731-740.

O'Brien JA, Lemaire W, Wittmann M, Jacobson MA, Ha SN, Wisnoski DD, Lindsley CW, Schaffhauser HJ, Rowe B, Sur C, Duggan ME, Pettibone DJ, Conn PJ and Williams DL, Jr. (2004) A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. *J Pharmacol Exp Ther* **309**:568-577.

Pisani A, Bernardi G, Ding J and Surmeier DJ (2007) Re-emergence of striatal cholinergic interneurons in movement disorders. *Trends in Neurosciences* **30**:545-553.

Raedler TJ, Bymaster FP, Tandon R, Copolov D and Dean B (2007) Towards a muscarinic hypothesis of schizophrenia. *Molecular Psychiatry* **12**:232-246.

Sanchez-Lemus E and Arias-Montano JA (2006) M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices. *Neurochemical Research* **31**:555-561.

Scarr E, Sundram S, Keriakous D and Dean B (2007) Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. *Biological Psychiatry* **61**:1161-1170.

JPET #140350

- Shekhar A, Potter WZ, Lienemann J, Sunblad K, Lightfoot J, Herrera J, Unverzagt F, Bymaster FP and Felder C (2001) Efficacy of xanomeline, a selective muscarinic agonist, in treating schizophrenia: A Double-Blind, Placebo Controlled Study. *American College of Neuropsychopharmacology, 40th Annual Meeting, Waikoloa, Hawaii.*
- Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. *Am J Psychiatry* **165**:1033-1039.
- Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM and Conn PJ (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. *Nature Chemical Biology* **4**:42-50.
- Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM and Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. *Journal of Pharmacology & Experimental Therapeutics* **299**:782-792.
- Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C and Nomikos GG (2004) M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies. *FASEB Journal* **18**:1410-1412.
- Wess J (1996) Molecular biology of muscarinic acetylcholine receptors. *Critical Reviews in Neurobiology* **10**:69-99.
- Zhao Z, Wisnoski DD, O'Brien JA, Lemaire W, Williams DL, Jr., Jacobson MA, Wittman M, Ha SN, Schaffhauser H, Sur C, Pettibone DJ, Duggan ME, Conn PJ, Hartman GD and Lindsley CW (2007) Challenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. *Bioorganic & Medicinal Chemistry Letters* **17**:1386-1391.

JPET #140350

### **Footnotes**

This work was supported by grants from the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke. AEB is supported by NIMH grant 1F32 MH079678-01. CKJ was supported by NIMH grant 5 F32 MH076371-01 & 02. TMB is supported by the Integrative Training in Therapeutic Discovery (ITTD) grant from the Vanderbilt Institute of Chemical Biology (T90-DA22873) and JKS is supported by NIMH grant 1 F31 MH80559-01. Vanderbilt is a site in the National Institutes of Health-supported Molecular Libraries Screening Center Network.

Reprint requests should be sent to Craig W. Lindsley, Ph.D., Department of Pharmacology, Vanderbilt University Medical Center, 2215B Garland Ave. 12415D Medical Research Building IV, Nashville, TN 37232-0575.

JPET #140350

## Legends for Figures

**Figure 1.** Chemical structures of xanomeline [3-[3-hexyloxy-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine], (1) and VU10010 [3-amino-*N*-(4-chlorobenzyl)-4,6-dimethylthieno[2,3-*b*]pyridine-2-carboxamide],(2).

**Figure 2. Chemical Optimization of VU10010 using a diversity-oriented approach to achieve soluble, centrally penetrant M<sub>4</sub> positive allosteric modulators.** (A.) β-aminoamide as a potential P-gp liability in series 3 and cyclization strategy to diminish this liability in series 4. (B.) Solution phase parallel synthesis of libraries of VU10010 analogs. Commercial heterocyclic carboxylic acids 5 (X, Y = C or N) were coupled to 12 different amines (HNR<sub>1</sub>R<sub>2</sub>) to afford focused libraries of VU10010 analogs 7-15 in yields ranging from 15% to 99%. C. Generic structures of analogs of VU10010 evaluated in the chemical lead optimization program in an effort to develop soluble, brain penetrant M<sub>4</sub> positive allosteric modulators.

**Figure 3. Screening paradigm for analog libraries 2-12 allowing for the rapid triage of inactive analogs.** A representative library of 61 analogs (scaffold 7) were tested at a single concentration (10μM) for their ability to potentiate an EC<sub>20</sub> concentration of ACh in CHO K1 cells stably co-expressing the rat M<sub>4</sub> mAChR and the chimeric G protein, G<sub>qi5</sub>. Calcium mobilization was measured using a Flexstation II, as described in Methods. Of those tested, 16 compounds (denoted by an asterisk) were selected for further evaluation. The response to an EC<sub>20</sub> concentration of ACh alone is shown in the bar on the far left and this level of activity is indicated by the solid line spanning the panel. Thus, test compounds increasing the % Max ACh Response above this level are considered potentiators of the M<sub>4</sub> mAChR. VU10010 was included as a positive control. Bars represent the mean ± S.E.M. of 3 or more determinations, each performed in duplicate.



JPET #140350

**Figure 4. VU0152099 and VU0152100 are potent positive allosteric modulators of rat M<sub>4</sub> in a functional calcium mobilization assay.** (A,D.) Chemical structure of VU0152099 (7o) (A.) and VU0152100 (7p) (D.). (B,E.) Potency of VU0152099 (403±117nM) (B.) and VU0152100 (380±93nM) (E.) was evaluated at the rM<sub>4</sub> receptor by measuring calcium mobilization in Chinese hamster ovary (CHO) cells stably expressing rM<sub>4</sub> and the chimeric G-protein, G<sub>qi5</sub>. A range of concentrations of test compound was added to cells, followed 1.5 minutes later by addition of an EC<sub>20</sub> concentration of ACh (ACh EC<sub>20</sub>). In the absence of an EC<sub>20</sub> concentration of ACh (Vehicle), neither test compound elicited a response. Data were normalized as a percent of the maximal response to 10µM ACh and represent the mean± S.E.M. of three independent experiments. (C,F.) VU0152099 (C.) and VU0152100 (F.) potentiate the response of rM<sub>4</sub> to ACh, as manifest by a dose-dependent leftward shift in the ACh CRC. At the highest concentrations tested, VU0152099 (30µM) induced a 30-fold shift and VU0152100 (10µM) induced a 70 fold shift in the ACh CRC. Data were normalized as a percent of the maximal response to 10µM ACh and represent the mean ± S.E.M. of 3-5 independent experiments.

**Figure 5. VU0152099 and VU0152100 potentiate GIRK-mediated thallium flux in response to ACh in HEK cells expressing human M<sub>4</sub>.** (A.) Both VU0152099 (■) and VU0152100 (▲) potentiate hM<sub>4</sub> - induced GIRK-mediated thallium flux in response to an EC<sub>20</sub> concentration of ACh with potencies of 1.2±0.3µM and 1.9±0.2 µM, respectively. (B.) In the presence of 10µM VU0152099 (▲) and VU0152100 (▼), the ACh CRC for induction of GIRK-mediated thallium flux was leftward shifted (≈30-fold) from 77±1.2 nM (■, Veh) to 2.09±0.3 nM (▲, VU0152099) and 2.35±0.5 nM (▲, VU0152100). Data were normalized as a percent of the maximal response to 10µM ACh and represent the mean ± S.E.M. of 3-4 independent experiments performed in quadruplicate.

**Figure 6. VU0152099 and VU0152100 bind allosterically and increase ACh affinity at rM<sub>4</sub>.** (A.) In competition binding studies, neither VU0152099 (■) nor VU0152100 (▲) displaced the orthosteric

JPET #140350

radioligand, [<sup>3</sup>H]-NMS (0.1nM), at concentrations up to 30μM. However, the orthosteric antagonist, atropine (▲), potently inhibited [<sup>3</sup>H]-NMS binding with a K<sub>i</sub> of 0.54 ± 0.1nM. (B.) In the presence of vehicle alone, an increasing concentration of ACh displaces [<sup>3</sup>H]-NMS (0.1nM) binding with a K<sub>i</sub> of 252±17.9 nM (■). In the presence of a fixed concentration (10μM) of VU0152099 or VU0152100, the potency of ACh to displace [<sup>3</sup>H]-NMS binding is shifted leftward, yielding K<sub>i</sub> values of 10.4 ±0.91 nM (▼, VU0152099) and 12.2±0.49 nM (▲, VU0152100), which represent a 25-fold and 21-fold shift in ACh potency, respectively. Data represent the mean ± S.E.M. of 3 independent experiments, performed in duplicate.

**Figure 7. VU0152099 (A.) and VU0152100 (B.) are functionally selective for the M<sub>4</sub> mAChR subtype.** No shift in the ACh CRC was observed in the presence of 30μM test compound at CHO K1 cells stably expressing M<sub>1</sub>, M<sub>2</sub>-G<sub>qi5</sub>, M<sub>3</sub>, or M<sub>5</sub> mAChRs. Calcium mobilization was measured in response to increasing concentrations of ACh following preincubation with either vehicle or test compound (30μM), as described in Methods. Assay of M<sub>1</sub>, M<sub>3</sub>, and M<sub>5</sub> mAChRs took advantage of endogenous coupling to G<sub>q</sub> proteins, whereas assay of M<sub>2</sub> activity required use of cells co-expressing the chimeric G protein, G<sub>qi5</sub>, to allow coupling of this receptor to calcium mobilization. Points represent the mean ± S.E.M. of three independent experiments.

**Figure 8. Pharmacokinetic profiling of VU0152099 and VU0152100 in rats.** Concentration-time profile of VU0152099 (A.) and VU0152100 (B.) in brain and plasma of male Sprague Dawley rats following a 56.6 mg/kg *i.p.* administration of each compound. Blood and brain tissue were collected at 0.5, 1, 2, and 4h after injection. Samples were extracted as described in Methods and analyzed by LC-MS-MS. Each time point represents the mean determination ± S.E.M. of three rats.


JPET #140350

**Figure 9. VU0152099 and VU0152100 inhibit amphetamine-induced hyperlocomotor activity in rats**

**without causing sedation.** (A.) Rats were pretreated for 30 min with vehicle or a 56.6 mg/kg dose of either VU0152099 or VU0152100 *i.p.*(not shown). Next, all rats received an injection of 1 mg/kg *s.c.* of amphetamine and locomotor activity was measured for an additional 60 min. Each point represents the mean of eight-sixteen rats. The Error bars represent  $\pm$  S.E.M. and are absent when less than the size of the point. Abscissa, dose of drug in milligrams per kilogram; ordinate, ambulations or total beam breaks per 5 min intervals; \*,  $P < 0.05$  versus veh+amphetamine control group, Dunnett's test. (B.) Lack of effect of VU0152100 on motor performance on the Rotorod. After initial training trials, rats were pretreated for 30 minutes *i.p.* with vehicle or a dose of VU0152100, specifically 30, 56.6 or 100 mg/kg, and then the time each animal remained on the rotorod was recorded; animals not falling off the rotorod were given a maximum score of 85 sec. Abscissa, dose of VU0152100 in milligrams per kilogram; ordinate, time spent on the rotorod in sec. Each bar graph represents the mean of eight-ten rats. The error bars represent  $\pm$  S.E.M.

JPET #140350

**Table 1. Structures, activities and ACh CRC fold-shifts of M<sub>4</sub> PAM analogs 7.** Subtle substitution changes on the arene ring lost 5-10-fold in terms of M<sub>4</sub> EC<sub>50</sub> and/or fold-shift of the ACh CRC. For instance, **7d**, in which the 4-Cl moiety of VU10010 is moved to the 3-position results in a loss in potency of over 9-fold (EC<sub>50</sub> = 3.7 μM). Similarly, the unsubstituted phenyl congener **7a** retains M<sub>4</sub> PAM activity (EC<sub>50</sub> = 630 nM), but the fold-shift diminishes to 8.6-fold, *versus* the 47-fold shift observed for VU10010 (Shirey et al., 2008). Compounds **7o** (VU0152099) and **7p** (VU0152100) retained M<sub>4</sub> PAM activity comparable to VU10010 (EC<sub>50</sub> values of 403 ± 117 nM and 380 ± 93 nM, respectively).



Compd	R	rat M <sub>4</sub> EC <sub>50</sub> (μM) <sup>a</sup>	rat M <sub>4</sub> ACh fold-shift
<b>7a</b>		0.63	8.6
<b>7b</b>		0.83	11.8
<b>7c</b>		1.83	ND
<b>7d</b>		3.70	ND
<b>7e</b>		2.63	ND
<b>7f</b>		2.04	ND
<b>7g</b>		2.88	ND
<b>7h</b>		1.44	ND
<b>7i</b>		1.80	ND
<b>7j</b>		2.96	ND
<b>7k</b>		3.04	ND
<b>7l</b>		0.88	ND
<b>7m</b>		1.12	ND
<b>7n</b>		0.72	13.7
<b>7o</b>		0.40	29.7
<b>7p</b>		0.38	70.1


<sup>a</sup>EC<sub>50</sub>s and fold-shifts are an average of at least 3 determinations; ND, not determined

JPET #140350


**Table 2. Pharmacokinetic Analysis of VU0152099 and VU0152100.** AUC(0-∞) and t<sub>1/2</sub> values of VU0152099 and VU0152100 in exposure studies in male rats after 56.6 mg/kg intraperitoneal administration. Values represent mean ± S.E.M. (n=3 rats).

<b>PK Parameter</b>	<b>VU0152099</b>	<b>VU0152100</b>
Mean AUC (0-∞) brain (ng.h/g)	4751.80 ± 666.17	5726.35 ± 694.68
Mean AUC(0-∞) plasma (ng.h/ml)	11928.00 ± 1472.36	6570.35 ± 235.87
AUC brain / AUC plasma	0.39 ± 0.01	0.86 ± 0.08
t <sub>1/2</sub> plasma (h)	1.66 ± 0.39	1.62 ± 0.69
t <sub>1/2</sub> brain (h)	1.25 ± 0.023	1.12 ± 0.01

**Fig. 1**






**1, xanomeline**




**2, VU10010**







# Fig. 2



**Fig. 3**







**Fig. 4****A.****VU0152099 (7o)****B.****D.****VU0152100 (7p)****E.****C.****F.**



**Fig. 5**



**A.**






**B.**



**Fig. 6****A.****B.**

**Fig. 7****A.****B.**

**Fig. 8****A.****VU0152099****B.****VU0152100**

**Fig. 9****A.****B.**